A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
377actual
Sites
53
Countries
Australia, Canada, Germany +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-18 | actual | When the study began enrolling |
| Primary completion | 2026-05-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-11 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity or Overweight
Interventions
- Drug: AZD9550
- Drug: AZD6234
- Drug: Placebo comparator
Primary outcomes
what the primary-completion date above is the date OFPercent change in body weight from baseline after 36 weeks of treatment
measured 36 weeks
Weight loss ≥ 5% from baseline after 36 weeks of treatment
measured 36 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed